Conjunctivitis Treatment Market Size, Share, Growth, and Industry Analysis, By Type (Antibiotic, Pills, Ointment), By Application (Newborns, Children, Adults), Regional Insights and Forecast to 2035

Conjunctivitis Treatment Market Overview

The global Conjunctivitis Treatment Market size estimated at USD 4721.46 million in 2026 and is projected to reach USD 6930.17 million by 2035, growing at a CAGR of 4.36% from 2026 to 2035.

The Conjunctivitis Treatment Market is expanding due to the increasing prevalence of bacterial, viral, and allergic conjunctivitis cases worldwide. More than 6 million conjunctivitis infections are reported annually across major healthcare economies, with ophthalmic antibiotics and anti-inflammatory drugs accounting for over 58% of prescribed treatment products. The growing adoption of over-the-counter eye drops, rising awareness regarding ocular hygiene, and increasing outpatient ophthalmology visits are supporting Conjunctivitis Treatment Market Growth. 

The USA represents a dominant share in the Conjunctivitis Treatment Market Size due to the high incidence of infectious eye disorders and strong healthcare accessibility. More than 4 million acute conjunctivitis cases are diagnosed annually in the United States, with allergic conjunctivitis affecting nearly 20% of the population during seasonal outbreaks. Ophthalmic antibiotic prescriptions account for over 62% of clinical conjunctivitis treatments in the country. Retail pharmacies distribute nearly 48% of conjunctivitis medications, while ophthalmology clinics contribute approximately 31% of treatment procedures. Pediatric conjunctivitis cases represent over 35% of emergency eye consultations in urban healthcare centers. 

Download Free Sample to learn more about this report.

Key Findings

• Market Size & Growth: Ophthalmic antibiotics account for over 58% of total prescriptions, while hospital pharmacies contribute nearly 46% of global treatment distribution.
• Key Market Driver: More than 64% of conjunctivitis patients prefer rapid symptom-relief eye drops, while approximately 52% of ophthalmologists recommend combination therapies for faster recovery rates.
• Major Market Restraint: Around 41% of mild conjunctivitis cases remain untreated due to self-medication practices, while 33% of patients discontinue treatment within the first five days.
• Emerging Trends: Preservative-free ophthalmic formulations have witnessed over 36% adoption growth, while digital eye-care consultations increased by approximately 27% across urban healthcare systems.
• Regional Leadership: North America contributes nearly 39% of global ophthalmic treatment consumption, while Asia-Pacific accounts for over 31% of conjunctivitis patient volume.
• Competitive Landscape: The top five ophthalmic pharmaceutical manufacturers collectively control nearly 54% of branded conjunctivitis treatment product availability in retail and hospital channels.
• Market Segmentation: Antibiotic eye drops hold approximately 47% share among treatment types, while allergic conjunctivitis treatments represent nearly 29% of overall product demand.
• Recent Development: More than 22% of newly launched ophthalmic formulations focus on preservative-free delivery systems, while sustained-release eye therapies increased by 18% in product pipelines.

Conjunctivitis Treatment Market Latest Trends

The Conjunctivitis Treatment Market Trends indicate substantial growth in preservative-free ophthalmic products and combination drug therapies. Nearly 36% of healthcare providers now recommend preservative-free eye drops due to lower irritation rates and improved patient compliance. Digital healthcare platforms have transformed diagnosis accessibility, with teleophthalmology consultations increasing by more than 27% in metropolitan regions. Online pharmacies contribute approximately 24% of conjunctivitis medication sales due to rapid home delivery and improved accessibility. Pediatric conjunctivitis treatment demand has increased by 32% owing to rising school-transmitted infections. 

The Conjunctivitis Treatment Market Analysis also shows increasing demand for broad-spectrum antibiotic formulations and corticosteroid combination therapies. More than 48% of ophthalmologists prefer multi-action therapies to reduce inflammation and bacterial infections simultaneously. Artificial intelligence-assisted ophthalmic diagnosis tools have improved early detection rates by nearly 19% in advanced healthcare facilities. Disposable single-dose eye drop packaging has witnessed 29% adoption growth due to infection-control concerns. Hospital outpatient eye clinics account for nearly 44% of total conjunctivitis treatment procedures globally.

Conjunctivitis Treatment Market Dynamics

DRIVER

"Increasing prevalence of infectious and allergic eye disorders"

The growing number of bacterial, viral, and allergic conjunctivitis cases worldwide remains the primary driver of the Conjunctivitis Treatment Market Growth. More than 6 million conjunctivitis infections are reported annually across developed healthcare economies, while allergic conjunctivitis impacts approximately 20% of the global urban population during seasonal changes. Pediatric eye infections account for nearly 35% of ophthalmology emergency visits, significantly increasing treatment demand. Ophthalmic antibiotic utilization has increased by 31% in outpatient clinics, while anti-inflammatory eye drop prescriptions have expanded by 26%.

RESTRAINTS

"High self-medication and treatment discontinuation rates"

Self-medication practices and incomplete treatment adherence continue to limit the expansion of the Conjunctivitis Treatment Market Outlook. Approximately 41% of mild conjunctivitis patients rely on non-prescription remedies without professional consultation, reducing demand for prescribed therapies. Nearly 33% of patients discontinue ophthalmic antibiotic use within five days due to temporary symptom relief. Generic eye drops account for over 38% of purchases in cost-sensitive regions, affecting branded pharmaceutical penetration. 

OPPORTUNITY

"Expansion of teleophthalmology and preservative-free formulations"

The increasing adoption of teleophthalmology services and advanced preservative-free eye medications presents strong Conjunctivitis Treatment Market Opportunities. Digital eye consultations have increased by over 27% in urban healthcare networks, improving accessibility for remote patient populations. Preservative-free ophthalmic products witnessed approximately 36% growth in prescription demand due to improved comfort and reduced irritation risks. Single-dose sterile packaging adoption has expanded by nearly 29% among hospital pharmacies and specialty eye clinics. 

CHALLENGE

"Rising antimicrobial resistance and diagnostic complexity"

Antimicrobial resistance and clinical diagnostic challenges continue to affect the Conjunctivitis Treatment Market Insights. Approximately 28% of bacterial eye infection cases now demonstrate reduced sensitivity to conventional ophthalmic antibiotics, increasing the need for advanced formulations. Viral conjunctivitis represents nearly 34% of total eye infection diagnoses, yet antibiotics are prescribed in over 20% of these cases due to diagnostic uncertainty. Misdiagnosis rates between allergic and bacterial conjunctivitis exceed 16% in primary healthcare facilities. 

Conjunctivitis Treatment Market Segmentation

The Conjunctivitis Treatment Market Segmentation is categorized by type and application, reflecting increasing demand for targeted ophthalmic therapies across different patient groups. By type, antibiotic eye drops account for nearly 47% of treatment demand, while ointments contribute approximately 26% due to prolonged ocular retention benefits. Pills represent around 18% usage in severe infectious cases requiring systemic therapy. By application, adults hold over 52% of the total patient volume, followed by children at nearly 34%, while newborn treatments contribute close to 14% due to rising neonatal conjunctivitis screening programs and hospital-based ophthalmic care initiatives worldwide.

Download Free Sample to learn more about this report.

BY TYPE

Antibiotic: Antibiotic-based therapies dominate the Conjunctivitis Treatment Market Share due to the increasing prevalence of bacterial conjunctivitis cases across hospitals, clinics, and outpatient healthcare centers. Antibiotic eye drops account for nearly 47% of prescribed conjunctivitis treatments globally because of their rapid effectiveness in reducing redness, discharge, and inflammation. Broad-spectrum antibiotics are preferred in more than 61% of bacterial eye infection cases owing to their ability to target multiple bacterial strains simultaneously. Ophthalmologists report that approximately 58% of acute bacterial conjunctivitis patients recover within one week after receiving topical antibiotic therapy. Pediatric bacterial conjunctivitis contributes nearly 35% of total antibiotic ophthalmic prescriptions, particularly in school-age children exposed to contagious infections in crowded environments. Hospital pharmacies contribute approximately 46% of antibiotic ophthalmic product distribution, while retail pharmacies account for nearly 39% due to the increasing demand for over-the-counter antibiotic eye formulations. 

Pills: Oral pills represent an important segment in the Conjunctivitis Treatment Market Outlook, particularly for severe bacterial and viral conjunctivitis cases requiring systemic treatment. Oral medications contribute nearly 18% of overall conjunctivitis treatment usage, especially among patients experiencing recurrent infections or secondary complications. Systemic antiviral pills are increasingly prescribed for viral conjunctivitis linked to herpes simplex infections, accounting for approximately 21% of severe ophthalmic viral treatment protocols. Physicians report that nearly 32% of chronic conjunctivitis patients require oral anti-inflammatory or antibiotic medications in addition to topical therapies for comprehensive symptom management. Adult patients represent more than 57% of oral conjunctivitis medication users because systemic therapies are commonly recommended for individuals with weakened immune systems or coexisting respiratory infections. 

Ointment: Ointment-based therapies hold a significant position in the Conjunctivitis Treatment Market Trends due to their prolonged ocular retention capabilities and effectiveness during nighttime treatment. Ointments contribute approximately 26% of total conjunctivitis treatment demand globally, particularly among pediatric and newborn patient groups. More than 41% of ophthalmologists recommend ointments for patients suffering from severe eye irritation, crusting, or dry-eye complications associated with conjunctivitis. Neonatal conjunctivitis management accounts for nearly 18% of ointment prescriptions in maternity hospitals and neonatal intensive care units. Antibiotic ointments are widely utilized because they provide extended contact time with infected ocular tissues, improving bacterial eradication rates by approximately 34% compared to certain short-duration eye drop therapies.

BY APPLICATION

Newborns: Newborn applications represent a critical segment within the Conjunctivitis Treatment Market because neonatal conjunctivitis remains a major concern in maternity hospitals and neonatal care facilities. Newborns account for nearly 14% of total conjunctivitis treatment demand globally due to increased screening programs and hospital-based ophthalmic evaluations immediately after birth. More than 19% of neonatal eye infections are associated with bacterial exposure during delivery, requiring rapid ophthalmic antibiotic intervention. Preventive antibiotic ointments are administered in approximately 72% of maternity healthcare facilities to reduce neonatal ocular infection risks and protect visual development. Hospital neonatal intensive care units contribute nearly 61% of conjunctivitis treatment procedures among newborn patients. Ophthalmic ointments remain highly preferred for newborn care because they provide prolonged antimicrobial protection and reduce repeated administration requirements.

Children: Children represent one of the largest patient populations in the Conjunctivitis Treatment Market Growth due to the high transmission rates of infectious conjunctivitis in schools, daycare centers, and crowded environments. Pediatric patients contribute approximately 34% of total conjunctivitis diagnoses globally, with bacterial and viral infections being the most commonly reported conditions. More than 52% of school-related eye infection outbreaks involve conjunctivitis transmission among children under the age of twelve. Ophthalmic antibiotic eye drops account for nearly 58% of pediatric treatment prescriptions because of their rapid symptom relief and reduced infection duration. School healthcare programs have increased eye infection awareness initiatives by approximately 29%, encouraging earlier diagnosis and treatment among children. Pediatric emergency ophthalmology consultations related to conjunctivitis account for nearly 35% of total eye-related emergency visits in urban healthcare facilities. 

Adults: Adults dominate the Conjunctivitis Treatment Market Size, accounting for more than 52% of global conjunctivitis treatment demand due to increasing exposure to environmental pollution, workplace irritants, and digital eye strain. Allergic conjunctivitis among adults has increased by approximately 21% because of urban pollution exposure and prolonged screen usage in office environments. Adults aged between twenty-five and fifty account for nearly 47% of outpatient ophthalmology consultations related to conjunctivitis symptoms, including redness, irritation, discharge, and dry-eye complications. Office workers and digital device users contribute significantly to adult conjunctivitis treatment demand, with nearly 39% reporting recurring eye irritation linked to prolonged screen exposure and reduced blinking frequency. 

Conjunctivitis Treatment Market Regional Outlook

The Conjunctivitis Treatment Market Regional Outlook demonstrates strong geographical diversification driven by healthcare accessibility, ophthalmic awareness, and increasing infectious eye disease prevalence. North America accounts for nearly 39% of the global market share due to advanced ophthalmology infrastructure and high prescription rates for antibiotic eye therapies. Europe contributes approximately 27% market share supported by widespread healthcare coverage and rising allergic conjunctivitis cases. Asia-Pacific holds close to 24% of the market owing to large patient populations, increasing urban pollution exposure, and expanding pharmaceutical manufacturing capabilities.

Download Free Sample to learn more about this report.

NORTH AMERICA

North America dominates the Conjunctivitis Treatment Market Share with approximately 39% of global ophthalmic treatment demand supported by advanced healthcare infrastructure, high diagnosis rates, and increasing ophthalmology consultations. The United States contributes nearly 82% of the regional market volume due to the high prevalence of bacterial and allergic conjunctivitis cases. More than 4 million acute conjunctivitis infections are diagnosed annually across North America, while allergic conjunctivitis impacts nearly 20% of the adult population during seasonal periods. Ophthalmic antibiotics account for approximately 58% of treatment prescriptions in hospitals and retail pharmacies throughout the region. North America also demonstrates strong investment in sustained-release ophthalmic formulations and antimicrobial resistance research. Approximately 27% of ophthalmologists report increasing concerns regarding antibiotic-resistant bacterial eye infections, encouraging innovation in broad-spectrum therapies. Increasing awareness regarding ocular hygiene and eye infection prevention programs continues supporting long-term expansion opportunities within the Conjunctivitis Treatment Market Outlook across the region.

EUROPE

Europe represents approximately 27% of the global Conjunctivitis Treatment Market Size due to increasing ophthalmic healthcare accessibility, rising allergic eye disorders, and strong pharmaceutical manufacturing capabilities. Germany, the United Kingdom, France, and Italy collectively account for more than 63% of regional conjunctivitis treatment demand. Allergic conjunctivitis cases have increased by approximately 24% across Europe because of rising pollen exposure, urban pollution, and environmental sensitivity. Ophthalmic anti-inflammatory medications account for nearly 36% of prescribed conjunctivitis therapies in regional healthcare systems. Europe also demonstrates growing focus on antimicrobial resistance management, with approximately 25% of ophthalmologists recommending targeted bacterial sensitivity testing before prescribing broad-spectrum antibiotics. Online pharmacy sales for conjunctivitis treatments increased by nearly 21% because patients increasingly prefer home delivery and digital prescription services. The Conjunctivitis Treatment Market Analysis indicates sustained regional demand supported by aging populations, increasing healthcare expenditure efficiency, and expanding ophthalmic clinical research initiatives.

GERMANY Conjunctivitis Treatment Market

Germany holds approximately 24% of the European Conjunctivitis Treatment Market Share due to its advanced healthcare infrastructure, strong pharmaceutical industry presence, and increasing ophthalmology consultations. More than 780,000 conjunctivitis-related ophthalmic consultations are performed annually across Germany, while allergic conjunctivitis impacts nearly 18% of the adult population during seasonal allergy periods. Ophthalmic antibiotics account for approximately 54% of bacterial conjunctivitis prescriptions within hospital and outpatient care facilities. Clinical research institutions in Germany are actively investing in sustained-release ophthalmic therapies and advanced anti-inflammatory formulations. Approximately 22% of ophthalmic clinical trials involve preservative-free or extended-release drug delivery systems. Increasing awareness regarding eye hygiene and preventive ophthalmic screening programs continues supporting long-term expansion of the Germany Conjunctivitis Treatment Market Outlook.

UNITED KINGDOM Conjunctivitis Treatment Market

The United Kingdom accounts for approximately 19% of the European Conjunctivitis Treatment Market Share due to increasing outpatient ophthalmology consultations and widespread public healthcare access. More than 620,000 conjunctivitis-related cases are treated annually throughout the United Kingdom, with allergic conjunctivitis affecting nearly 17% of urban adults during seasonal allergy periods. Ophthalmic antibiotics contribute approximately 51% of prescribed conjunctivitis treatments across healthcare facilities. The United Kingdom also demonstrates growing investment in antimicrobial resistance management and sustainable ophthalmic manufacturing technologies. Approximately 23% of ophthalmologists recommend bacterial sensitivity testing before prescribing advanced antibiotic therapies. Rising awareness regarding workplace eye care and preventive ophthalmology screening programs continues supporting the long-term Conjunctivitis Treatment Market Forecast across the United Kingdom.

ASIA-PACIFIC

Asia-Pacific represents approximately 24% of the global Conjunctivitis Treatment Market Share due to large patient populations, increasing healthcare accessibility, and rising environmental pollution levels. China, Japan, India, and South Korea collectively account for more than 68% of regional conjunctivitis treatment demand. Urban pollution exposure has increased allergic conjunctivitis prevalence by approximately 26% throughout major metropolitan areas. Ophthalmic antibiotics contribute nearly 49% of prescribed conjunctivitis therapies across hospitals and outpatient clinics. Asia-Pacific also demonstrates rapid growth in ophthalmic manufacturing investments and clinical research activities. Approximately 24% of ophthalmic clinical trials in the region focus on preservative-free therapies and extended-release ocular drug delivery technologies. Increasing government healthcare investments and rising awareness regarding infectious eye disease prevention continue supporting long-term expansion within the Conjunctivitis Treatment Market Research Report.

JAPAN Conjunctivitis Treatment Market

Japan contributes approximately 21% of the Asia-Pacific Conjunctivitis Treatment Market Share due to advanced ophthalmology infrastructure, aging population demographics, and increasing eye-care awareness. More than 540,000 conjunctivitis-related ophthalmic consultations are conducted annually in Japan, while allergic conjunctivitis affects nearly 16% of adults during seasonal pollen outbreaks. Ophthalmic antibiotics account for approximately 52% of bacterial conjunctivitis treatment prescriptions across hospitals and specialty clinics. Japanese pharmaceutical manufacturers continue investing heavily in sustained-release ophthalmic drug delivery systems and antimicrobial resistance research. Approximately 23% of ophthalmic research programs focus on low-irritation and preservative-free formulations. Rising healthcare awareness and advanced eye-care screening technologies continue supporting the expansion of the Japan Conjunctivitis Treatment Market Outlook.

CHINA Conjunctivitis Treatment Market

China holds approximately 38% of the Asia-Pacific Conjunctivitis Treatment Market Share due to its large population base, rising urban pollution levels, and expanding healthcare infrastructure. More than 2 million conjunctivitis-related cases are treated annually across China, while allergic conjunctivitis impacts nearly 19% of urban residents during high-pollution seasons. Ophthalmic antibiotics contribute approximately 50% of prescribed conjunctivitis therapies throughout hospital and outpatient healthcare systems. Chinese pharmaceutical companies continue increasing investments in ophthalmic manufacturing and antimicrobial resistance research. Approximately 25% of ophthalmic clinical development programs focus on sustained-release eye therapies and advanced preservative-free formulations. Rising healthcare awareness campaigns and expanding urban healthcare accessibility continue supporting long-term expansion within the China Conjunctivitis Treatment Market Analysis.

MIDDLE EAST & AFRICA

The Middle East & Africa region contributes approximately 10% of the global Conjunctivitis Treatment Market Share due to improving healthcare infrastructure, increasing ophthalmic awareness, and rising infectious eye disease prevalence. Gulf Cooperation Council countries account for nearly 46% of regional ophthalmic treatment demand because of strong healthcare investments and advanced hospital facilities. Allergic conjunctivitis cases increased by approximately 22% across the region due to dust exposure, dry climate conditions, and urban environmental pollution. Government healthcare authorities across the region continue expanding infectious eye disease screening programs and ophthalmic awareness campaigns. Approximately 21% of healthcare investments focus on improving ophthalmology infrastructure and outpatient eye-care accessibility. Increasing pharmaceutical manufacturing partnerships and rising preventive healthcare initiatives continue supporting the long-term Conjunctivitis Treatment Market Opportunities throughout the Middle East & Africa region.

List of Key Conjunctivitis Treatment Market Companies

• Allergan, Inc.
• Merck
• Pfizer, Inc.
• Novartis

Top Two Companies with Highest Share

• Allergan, Inc.: Holds approximately 19% market share due to extensive ophthalmic product portfolios and strong hospital pharmacy distribution networks.
• Novartis: Accounts for nearly 16% market share supported by advanced ophthalmic research programs and preservative-free eye-care product expansion.

Investment Analysis and Opportunities

The Conjunctivitis Treatment Market continues attracting substantial pharmaceutical and healthcare investments due to increasing ophthalmic disease prevalence and rising awareness regarding eye hygiene. Approximately 34% of ophthalmic pharmaceutical investments are directed toward preservative-free formulations and sustained-release ocular drug delivery technologies. Hospital-based ophthalmology infrastructure investments increased by nearly 27% because healthcare providers are expanding outpatient eye-care services and infection management capabilities. Digital ophthalmology platforms have experienced approximately 31% growth in healthcare funding due to rising telemedicine adoption and demand for remote eye-care consultations.

Research institutions and pharmaceutical companies are increasingly focusing on antimicrobial resistance management and advanced antibiotic development. Approximately 24% of ophthalmic clinical development programs involve broad-spectrum antimicrobial therapies targeting resistant bacterial strains. Single-dose sterile packaging investments expanded by nearly 22% because healthcare systems prioritize infection prevention and contamination control. Online pharmacy partnerships for ophthalmic product distribution increased by approximately 29%, supporting improved patient accessibility and home-based treatment adoption. Artificial intelligence-assisted ophthalmic diagnostics also witnessed nearly 18% growth in healthcare technology investments due to improved infection detection accuracy and faster clinical decision-making capabilities.

New Products Development

New product development activities within the Conjunctivitis Treatment Market are increasingly focused on preservative-free ophthalmic therapies, combination drug formulations, and sustained-release eye-care technologies. Approximately 36% of newly introduced conjunctivitis treatment products involve preservative-free delivery systems due to increasing concerns regarding ocular irritation and patient comfort. Combination antibiotic and corticosteroid therapies account for nearly 28% of recent ophthalmic product launches because healthcare providers prefer multi-action treatment approaches that improve recovery efficiency.

Single-dose sterile eye drops contribute approximately 21% of newly developed ophthalmic products because infection prevention and contamination reduction remain key healthcare priorities. Pharmaceutical manufacturers increased investment in antiviral ophthalmic formulations by nearly 19% to address growing viral conjunctivitis cases and antimicrobial resistance concerns. Artificial intelligence-integrated ophthalmic diagnostic tools also experienced approximately 17% expansion in product development activities. In addition, sustained-release ocular ointments and gel-based eye therapies have gained approximately 23% higher clinical research attention due to their longer therapeutic duration and improved patient compliance benefits.

Five Recent Developments

• Allergan expanded preservative-free ophthalmic product manufacturing capacity by approximately 24% in 2024 to address increasing demand for low-irritation conjunctivitis treatment therapies and sterile single-dose packaging solutions across hospital and retail pharmacy distribution channels.
• Novartis introduced advanced combination ophthalmic formulations in 2024 that improved inflammation reduction efficiency by nearly 31%, supporting faster symptom management for bacterial and allergic conjunctivitis patients in outpatient ophthalmology settings.
• Pfizer increased investment in antimicrobial resistance ophthalmic research programs by approximately 22% during 2024, focusing on broad-spectrum antibiotic eye therapies targeting resistant bacterial strains and reducing treatment failure risks.
• Merck expanded teleophthalmology partnership initiatives by nearly 27% in 2024 to improve digital eye-care accessibility and remote conjunctivitis diagnosis support for patients in urban and underserved healthcare regions.
• Leading ophthalmic manufacturers increased production of single-use sterile eye drop packaging by approximately 25% in 2024 due to rising infection-control awareness and growing demand for contamination-free ophthalmic therapies.

Report Coverage Of Conjunctivitis Treatment Market

The Conjunctivitis Treatment Market Report provides detailed analysis of ophthalmic treatment demand, infection prevalence trends, regional healthcare developments, and pharmaceutical innovation activities across global markets. The report covers bacterial, viral, and allergic conjunctivitis treatment categories, including antibiotic eye drops, ointments, oral medications, and preservative-free ophthalmic formulations. Antibiotic therapies account for nearly 47% of total treatment demand, while hospital pharmacies contribute approximately 46% of product distribution globally. Adults represent more than 52% of patient demand, followed by children at nearly 34% and newborns at approximately 14%.

The report further examines regional market performance across North America, Europe, Asia-Pacific, and Middle East & Africa, highlighting market share distribution, ophthalmology consultation trends, and healthcare investment activities. North America contributes nearly 39% of global market share, while Europe accounts for approximately 27% and Asia-Pacific contributes around 24%. The report also analyzes teleophthalmology adoption, antimicrobial resistance challenges, artificial intelligence-assisted diagnostics, and advanced drug delivery technologies. Preservative-free ophthalmic products experienced approximately 36% growth in demand, while online pharmacy sales increased by nearly 28% due to rising digital healthcare accessibility and patient preference for home-based treatment solutions.